Your browser is no longer supported. Please, upgrade your browser.
MTFB Motif Bio plc daily Stock Chart
Motif Bio plc
Index- P/E- EPS (ttm)-2.02 Insider Own- Shs Outstand296.66M Perf Week41.51%
Market Cap667.49M Forward P/E- EPS next Y- Insider Trans- Shs Float13.43M Perf Month20.32%
Income- PEG- EPS next Q- Inst Own7.46% Short Float0.52% Perf Quarter-61.21%
Sales- P/S- EPS this Y- Inst Trans- Short Ratio0.10 Perf Half Y-73.53%
Book/sh-0.22 P/B- EPS next Y- ROA- Target Price3.50 Perf Year-79.55%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range1.54 - 11.50 Perf YTD-65.86%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-80.43% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low46.10% ATR0.58
Employees8 Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)36.65 Volatility25.26% 13.16%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.70 Prev Close2.24
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume728.13K Price2.25
Recom2.80 SMA2022.45% SMA50-62.43% SMA200-71.05% Volume506,820 Change0.45%
Mar-20-19 07:46AM  The Daily Biotech Pulse: FDA Nod For Sage's Postpartum Depression Drug, Pfizer Invests In Gene Therapy Company Benzinga +55.28%
03:00AM  Motif Bio Granted Meeting with U.S. FDA regarding Iclaprim GlobeNewswire
Mar-18-19 03:00AM  Motif Bio Announces Appointment of Bruce Williams as Interim Chairman and Resignation of Richard Morgan from the Board GlobeNewswire
Feb-20-19 10:15AM  MTFB: FDA Issues CRL for Iclaprim Zacks Small Cap Research -11.36%
Feb-19-19 02:00AM  Motif Bio Conference Call and Webcast GlobeNewswire -18.22%
Feb-18-19 02:00AM  Motif BioSciences Enters into Amendment Agreement with Hercules Capital GlobeNewswire
Feb-14-19 02:00AM  Motif Bio Receives Complete Response Letter from the FDA GlobeNewswire -72.10%
Jan-17-19 10:00AM  Antimicrobials Working Group Announces Updates to Leadership Team PR Newswire +5.20%
Oct-31-18 03:00AM  Motif Bio to participate at upcoming Jefferies London Healthcare Conference GlobeNewswire
Oct-03-18 01:15PM  MTFB: Additional Data for Iclaprim Presented at ESCMID/ASM Zacks Small Cap Research
03:01AM  Motif Bio Presents New Iclaprim Data at IDWeek GlobeNewswire
Sep-25-18 02:00AM  Motif Bio Reports Half-Year 2018 Financial Results and Operational Progress GlobeNewswire
Sep-20-18 02:00AM  Motif Bio to Present Iclaprim Data at Upcoming Scientific Conferences GlobeNewswire
Sep-11-18 08:00AM  Danforth Advisors Names Robert Dickey IV Managing Director, Mid Atlantic Region GlobeNewswire
Sep-05-18 02:00AM  Motif Bio Presents Iclaprim Data at ESCMID/ASM Conference GlobeNewswire
Aug-21-18 03:00PM  MTFB: NDA for Iclaprim Accepted by FDA; PDUFA Date of Feb. 13, 2019 Zacks Small Cap Research
Aug-17-18 02:00AM  Motif Bio to Present Iclaprim Data at ESCMID/ASM Conference GlobeNewswire
Aug-14-18 02:00AM  Motif Bio Announces FDA Acceptance of New Drug Application with Priority Review for Iclaprim for Treatment of Acute Bacterial Skin and Skin Structure Infections GlobeNewswire +10.13%
Aug-09-18 02:00AM  Motif Bio to Present at Investor Events in August and September GlobeNewswire
Aug-08-18 02:00AM  Motif Bio Announces Notice of Allowance for Two U.S. Iclaprim Patents with Expiration in 2037 GlobeNewswire
Jul-03-18 02:00AM  Motif Bio Announces Resignation of Robert Bertoldi from Board of Directors GlobeNewswire
Jun-19-18 10:00AM  Result of Annual General Meeting GlobeNewswire
09:45AM  MTFB: Completes Submission of NDA for Iclaprim Zacks Small Cap Research
Jun-14-18 02:00AM  Motif Bio Submits NDA for Iclaprim GlobeNewswire
Jun-11-18 02:00AM  Motif Bio Announces New Iclaprim Data Presented at ASM Microbe 2018 GlobeNewswire
Jun-06-18 10:08AM  Antimicrobials Working Group Highlights Member Company Participation at ASM Microbe 2018 PR Newswire -8.57%
May-31-18 02:00AM  Motif Bio to present at Jefferies Global Healthcare Conference in New York GlobeNewswire +5.14%
May-09-18 02:00AM  Motif Bio Appoints Stephanie Noviello, MD, MPH as Vice President, Clinical Development GlobeNewswire
May-08-18 02:00AM  Motif Bio to Present Iclaprim Data at ASM Microbe 2018 GlobeNewswire
May-01-18 02:00AM  Motif Bio REVIVE-2 Phase 3 Study Results with Iclaprim Published in Peer-reviewed Journal, Antimicrobial Agents and Chemotherapy GlobeNewswire
Apr-25-18 11:00AM  MTFB: Initiates NDA Submission for Iclaprim Zacks Small Cap Research
Apr-20-18 10:17AM  Antimicrobials Working Group Highlights Member Company Participation at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) PR Newswire
Apr-19-18 02:00AM  Motif Bio Announces New Iclaprim Data being Presented at ECCMID 2018 GlobeNewswire -5.70%
Apr-17-18 02:00AM  Posting of UK Annual Report and Accounts & Notice of AGM GlobeNewswire
Apr-11-18 09:30AM  Motif Bio Announces Iclaprim Abstracts for ECCMID 2018 Now Online GlobeNewswire
Apr-10-18 02:00AM  Motif Bio Reports Fiscal Year 2017 Results GlobeNewswire
Apr-03-18 02:00AM  Motif Bio Initiates NDA Rolling Submission for Iclaprim and Provides Business Update GlobeNewswire +18.74%
Mar-20-18 07:50AM  Is It Too Late To Buy Motif Bio plc (NASDAQ:MTFB)? Simply Wall St. -6.84%
03:00AM  Motif Bio Update on NDA Submission for Iclaprim GlobeNewswire
Mar-19-18 03:00AM  Motif Bio to present at upcoming investor and scientific conferences GlobeNewswire
Feb-21-18 02:00AM  Motif Bio to Present Iclaprim Data at ECCMID 2018 GlobeNewswire
Feb-02-18 10:00AM  Appointment of Jonathan E. Gold as Interim Chief Financial Officer GlobeNewswire
Feb-01-18 01:00PM  MTFB: REVIVE-1 Results Published in Clinical Infectious Diseases Zacks Small Cap Research
Jan-29-18 10:17AM  Motif Bio PLC, Spero Therapeutics, Inc. and Vical Incorporated Join Antimicrobials Working Group PR Newswire +7.49%
Motif Bio plc, a clinical stage biopharmaceutical company, develops and commercializes pharmaceutical formulations in the United States. The company develops novel antibiotics for the treatment of serious and life-threatening infections caused by multi-drug resistant bacteria. Its lead product candidate is iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital-acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus, as well as to treat lung infections caused by Staphylococcus aureus in patients with cystic fibrosis. Motif Bio plc was incorporated in 2014 and is based in New York, New York.